Unleash Your Potential Xentria Meitheal, The Gateway to Collaboration

Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America. Xentria will license its experimental pulmonary sarcoidosis drug to ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... In June we entered a commercial agreement for XTMAB-16 with Meitheal Pharmaceuticals. Xentria received an up-front payment of $60 million ... Everlast Flooring Inc. TruCrowd Inc. Chicago Reading Specialists · Paisley & Elm · Mia's Dream Foundation · NKF Pharma · Meitheal® Pharmaceuticals · Xentria™ ... Xentria is a drug development company with ... In 2023, XTMAB-16 was exclusively licensed by Meitheal ... Founding President Tom Shea, MBA is also ... ... Meitheal拟与Xentria签署《许可协议》，Xentria授予被许可方在许可 ... Xentria,Inc（以下简称“Xentria”）目前不属于上市公司，公司未查询到其 ... Immunology. Study Phase : Phase I/ Phase II. Recipient : Xentria. Deal Size : $680.0 million. Deal Type : Licensing Agreement. DEALS_DEV arrow-down · Xentria ... Historic milestone for our company ! Tom is the founding CEO of Meitheal since its inception in 2017. In addition, Tom is also the founding President of Xentria, Inc. In addition, Victoria is the General Counsel & Corporate Secretary of Xentria, Inc. a biotech company focused on novel biologics and biosimilars, which was ...